Skip to main content

Table 4 Analyses of risk factors for poor clinical outcomes in the TB-HBV group (n = 58)

From: Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment

Factors Univariate analysis Multivariate analysis
OR 95%CI P-value OR 95%CI P-value
Age > 50 3.791 1.23, 11.69 0.020 3.317 0.91, 12.04 0.068
Male 2.625 0.27, 25.14 0.402
Alcohol intake > 40 g/d 5.069 0.58, 44.36 0.143 2.744 0.19, 40.15 0.461
INH + RFP 1.173 0.36, 3.80 0.790
Latency < 1 month 0.979 0.21, 4.57 0.978
Hepatocellular DILI 1.507 0.47, 4.80 0.488
Cirrhosis 4.76 1.44, 15.76 0.011 6.320 1.53, 26.06 0.011
HBV DNA > 20,000 IU/ml 3.800 1.16, 12.52 0.028 5.808 1.37, 24.64 0.017
NA treatment 1.071 0.36, 3.33 0.905
  1. Only variables with P < 0.200 in the univariate analysis were included in the multivariate analysis
  2. Abbreviations: INH isoniazid, RFP rifampin, DILI drug-induced liver injury, HBV hepatitis B virus, NA nucleos(t)ide analogue